UnitedHealth’s Third Guidance Raise Shows Margin Gains, but Volume Concerns Linger

What happened

UnitedHealth raised full-year 2026 adjusted EPS guidance for the third time this year, from at least $17.75 in January to at least $20.50 in October, while Optum Health swung to a $735 million quarterly operating profit from $41 million a year earlier. This marks a major sequential improvement for the value-based care arm, which had struggled with losses and restructuring, and supports management’s narrative that cost-control and care-management actions are gaining traction. The raise is consistent with the 88.1% MCR guidance highlighted in the prior master report, but the underlying mix of geographic and membership details remains thin. Revenue growth remains subdued, with prior filings showing premium revenue contraction and Medicare Advantage membership declines of roughly 1.1 million members in 2026, so this remains a margin-led rather than volume-led recovery. The market is likely to cheer the confirmation of earnings power, but investors should watch whether the improvement is sustainable without favorable reserve development or further cost-cutting that could impair franchise growth.

Implication

Investors should treat the third guidance raise as incremental validation of margin repair, but the stock at around $408.70 already prices in substantial recovery, as reflected in the 26x earnings multiple and above base-case implied value of $410. The Optum Health swing to profit is encouraging and may reduce a key bear-case driver, but durability depends on whether the improvement comes from sustainable operating changes or from one-time factors such as reserve releases or cost actions. Until 3Q26 and 4Q26 results confirm the improved Optum Health profitability without unusual items, and until Medicare Advantage enrollment shows signs of stabilizing in early 2027, the risk/reward skew remains neutral. A disciplined approach would be to wait for a pullback toward the $365 attractive entry level, or for hard evidence that membership declines are slowing and organic revenue growth returns. Conversely, a break above $445 would indicate the market is fully pricing in a more bullish scenario than current data support, prompting profit-taking.

Thesis delta

The new evidence nudges the thesis toward a more constructive view on margin recovery, especially in Optum Health, but does not yet resolve the core concern of shrinking membership and revenue base. We maintain a WAIT rating but lower the conviction slightly from 4.0 to 3.5 given the stronger-than-expected Optum Health turnaround, while keeping the base implied value at $410.